Table 3.
Primary BSI outcomes by study group.
| ILE received | P value | ||
|---|---|---|---|
| No | Yes | ||
| Group sizea | 627 (78%) | 180 (22%) | |
| CVAD days studied | 10,948 | 4616 | |
| Dwell time (CVAD days)b | 17.0 (8.1–24.0) | 24.9 (15.3–31.2) | <0.001c |
| Primary BSId | |||
| CLABSI | 57 (9%) | 15 (8%) | 0.882e |
| IR (95% CI) per 1000 CVAD days | 5.21 (4.02–6.75) | 3.25 (1.96–5.39) | |
| IRR (95% CI) | reference | 0.62 (0.33–1.12) | 0.097 |
| log‐rank test | 0.011 | ||
| MBI‐LCBI | 41 (7%) | 31 (17%) | <0.001e |
| IR (95% CI) per 1000 CVAD days | 3.74 (2.76–5.09) | 6.72 (4.72–9.55) | |
| IRR (95% CI) | reference | 1.79 (1.09–2.93) | 0.016 |
| log‐rank test | 0.614 | ||
Note: Frequencies and column percentages shown unless otherwise noted; percentages calculated with the number of nonmissing values in the denominator.
Abbreviations: BSI, bloodstream infection; CFU, colony‐forming unit; CLABSI, central line‐associated BSI; CVAD, central venous access device; ILE, intravenous lipid emulsion; IR, incidence rate; IRR, IR ratio; MBI‐LCBI, mucosal barrier injury laboratory‐confirmed bloodstream infection.
a
Row percentages shown.
b
Median (25th–75th percentiles) shown.
c
Wilcoxon rank sum test.
d
One patient was classified with a CLABSI and an MBI‐LCBI.
e
Fisher exact test.